Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
Sorafenib in advanced clear-cell renal-cell carcinoma
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials
Sorafenib Induces Growth Inhibition and Apoptosis of Human Chondrosarcoma Cells by Blocking the RAF/ERK/MEK Pathway
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway
Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism
Sorafenib - a small molecule with big promise?
Soraphinol B, a new acyloin compound produced by Sorangium cellulosum
Soraphinol C, a new free-radical scavenger from Sorangium cellulosum
Sorafenib in the treatment of metastatic renal cell cancer
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis (vol 418, pg 531, 2012)
Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis
Sorafenib in locally advanced or metastatic breast cancer
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
Sorafenib Down-regulates Expression of HTATIP2 to Promote Invasiveness and Metastasis of Orthotopic Hepatocellular Carcinoma Tumors in Mice
Sorafenib-Mediated Targeting of the AAA(+) ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/beta-catenin signaling
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
Sorafenib Combined with TACE in Advanced Primary Hepatocellular Carcinoma
Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase
Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal
Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells
Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer
Sorafenib induces autophagy and suppresses activation of human macrophage
Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
Sorafenib induces autophagy and suppresses activation of human macrophage (vol 15, pg 333, 2013)
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo
Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3 beta-dependent protein degradation
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1
Sorafenib Induces Autophagy in Human Myeloid Dendritic Cells and Prolongs Survival of Skin Allografts
Sorafenib硫脲衍生物的合成及活性研究
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence
Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials
Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient
Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study
Sorafenib Inhibition of Hepatic Stellate Cell Proliferation in Tumor Microenvironment of Hepatocellular Carcinoma: A Study of the Sorafenib Mechanisms
Sorafenib Blocks the HIF-1 alpha/VEGFA Pathway, Inhibits Tumor Invasion, and Induces Apoptosis in Hepatoma Cells
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappa B signaling
Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK
Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
Sorafenib therapy decreases the clearance of thyrotropin
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression
Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated
Sorafenib-Associated Psoriasiform Eruption in a Patient With Hepatocellular Carcinoma
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites
Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
Sorafenib tosylate as a radiosensitizer in malignant astrocytoma
Sorafenib Cardiotoxicity Increases Mortality After Myocardial Infarction
Sorafenib Enhances Radiation-Induced Apoptosis in Hepatocellular Carcinoma by Inhibiting STAT3
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis
Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells
Sorafenib prolongs liver regeneration after hepatic resection in rats
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Sorafenib exerts anti-glioma activity in vitro and in vivo (vol 478, pg 165, 2010)
Sorafenib: from literature to clinical practice
Sorafenib in patients with refractory or recurrent multiple myeloma
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation
Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells
Sorafenib-Induced Tumor Response in a Patient With Metastatic Epithelioid Angiomyolipoma
Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases
Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study
Sorafenib regulating ERK signals pathway in gastric cancer cell
Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
Sorad: a systems biology approach to predict and modulate dynamic signaling pathway response from phosphoproteome time-course measurements